NCT00679354: Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy |
|
|
| Completed | 2 | 30 | Canada, US | cilengitide, EMD 121974, laboratory biomarker analysis, pharmacological study, pharmacological studies | National Cancer Institute (NCI) | Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma | 10/10 | 07/11 | | |
NCT01517776 / 2009-011898-33: Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents |
|
|
| Terminated | 2 | 28 | Europe | Cilengitide, EMD 121974, Temozolomide, Temodal | Martin-Luther-Universität Halle-Wittenberg, Merck KGaA, Darmstadt, Germany | Gliomas | 03/14 | 04/14 | | |
NCT00006093: EMD 121974 in Treating Patients With Progressive or Recurrent Glioma |
|
|
| Completed | 1/2 | | US | cilengitide | New Approaches to Brain Tumor Therapy Consortium, National Cancer Institute (NCI) | Brain and Central Nervous System Tumors | | 10/06 | | |
